查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088881

視網膜疾病治療市場：依療法、給藥途徑、適應症、最終用戶和分銷管道分類－2026-2032年全球市場預測

Retinal Disorder Treatment Market by Treatment Modality, Route Of Administration, Disease Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，視網膜疾病治療市場將成長至 262.1 億美元，複合年成長率為 8.07%。

主要市場統計數據
基準年 2025 152.2億美元
預計年份：2026年 164億美元
預測年份 2032 262.1億美元
複合年成長率 (%) 8.07%

視網膜疾病的治療正從回顧性視力維護轉向早期診斷、持續疾病管理和精準干預。人口老化、糖尿病盛行率上升以及視網膜影像技術在基層醫療和眼科診療中的普及，是推動這一轉變的主要因素。世界衛生組織（世衛組織）報告稱，至少有22億人因近視或遠視而患有視力障礙，其中至少10億人本可預防或未得到治療，這凸顯了普及視網膜疾病診療服務的必要性。

治療的主要領域包括伴隨新生血管的老齡化黃斑部病變、糖尿病黃斑部水腫、糖尿病視網膜病變、視網膜靜脈阻塞、遺傳性視網膜營養不良和地圖狀萎縮。雖然抗VEGF療法仍然是多種棘手視網膜疾病的標準治療方法，補體抑制劑、基因療法、緩釋植入、生物相似藥和人工智慧輔助篩檢正在革新臨床路徑。根據國際糖尿病聯盟（IDF）的估計，2021年全球有5.37億成年人患有糖尿病，這進一步凸顯了篩檢和及時治療糖尿病視網膜病變的臨床緊迫性。

視網膜治療前景的變革性變化

視網膜疾病的治療正因長效生物製劑、新型作用機制以及對治療永續性的日益重視而改變。補體抑制劑已核准用於治療地圖狀萎縮，以及基因療法已廣泛應用於確診的雙等位基因RPE65突變相關視網膜營養不良，這些都顯示治療正朝著緩解疾病和精準治療的方向發展。

人工智慧對視網膜醫學的累積影響

人工智慧（AI）正整體成為視網膜疾病治療領域的重要驅動力，尤其是在篩檢、影像分診、疾病進展監測和工作流程最佳化方面。首個用於糖尿病視網膜病變檢測的自主AI系統於2018年獲得監管部門批准，這標誌著AI不再僅被視為一項實驗性技術，而是被認可為一種受監管的臨床工具。

視網膜疾病治療的主要區域趨勢

亞太地區糖尿病患者眾多，人口老化速度加快，都市區眼科醫療服務不斷擴展，光學同調斷層掃描（OCT）和眼底成像技術應用日益廣泛，因此該地區在視網膜疾病治療方面至關重要。中國、印度、日本、澳洲和韓國在該地區引領相關活動，這得益於三級眼科醫療體系的擴張和玻璃體內注射療法的廣泛應用。然而，成本效益、遍遠地區的醫療服務可及性、篩檢的連續性以及專科醫生的分佈仍然存在差異，因此，如何擴大糖尿病視網膜病變篩檢的規模並確保患者能夠獲得經濟有效的抗VEGF療法，成為當務之急。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東南亞國協，隨著糖尿病盛行率上升、都市區醫療投資增加以及數位醫療普及，視網膜篩檢和治療基礎設施正在不斷完善；然而，各成員國之間的經濟實力和眼科醫生密度存在顯著差異。在海灣合作理事會（GCC）國家，由於國家醫療改革計劃的支持以及糖尿病患病率較高（這增加了對糖尿病視網膜病變篩檢和長期視網膜護理的需求），專科醫院、數位醫療基礎設施、高品質藥物和慢性病管理被列為優先事項。

主要國家視網膜疾病治療趨勢

美國在視網膜疾病治療領域處於領先地位，這得益於生物製藥的廣泛應用、積極的臨床試驗、人工智慧輔助糖尿病視網膜病變篩檢的法規核准，以及在滿足報銷條件後迅速採用新的視網膜療法。加拿大則受益於其公共醫療保險體系、組織完善的專科醫療體系和強大的眼科學術網路。同時，墨西哥和巴西正透過公私合營合作醫療網路、都市區專科醫療中心以及不斷提高大眾對糖尿病相關眼科疾病的認知，擴大醫療服務的覆蓋範圍。

為視網膜疾病治療領域的領導者提供的實用建議

產業領導者應優先考慮那些展現出持續療效、安全性、真實世界用藥依從性優勢以及明確衛生經濟價值的療法。在競爭激烈的抗VEGF藥物領域，減少注射負擔、提高患者治療依從率以及針對疾病早期階段的治療方案能夠帶來顯著的差異化優勢，尤其是在生物類似藥價格壓力不斷增加以及支付方對治療頻率進行更嚴格審查的情況下。

視網膜疾病治療分析的調查方法

本執行摘要基於資訊來源，包括全球衛生組織和監管機構的資料庫、同行評審的眼科文獻、臨床試驗註冊庫、疾病流行病學出版物和公共衛生指南。數據已進行交叉核對，以確保與世界衛生組織 (WHO)、國際糖尿病聯盟 (IDF)、監管機構、美國疾病控制與預防中心 (CDC)、美國國立衛生研究院/國家眼科研究所 (NIH/NEI) 和主要眼科學會等權威資訊來源的數據保持一致。

結論：視網膜疾病治療的未來方向

視網膜疾病的治療正步入一個更加多元化的時代，其特點是生物製藥的持續療效、人工智慧驅動的檢測、精準醫療以及不斷擴展的治療模式。儘管抗VEGF療法仍然是治療的基礎，但補體抑制劑、基因療法、生物相似藥、緩釋製劑和數位篩檢正在拓展治療和診斷的領域。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 視網膜疾病治療市場：依治療方式分類

  • 藥物治療（藥品）
    • 抗 VEGF
    • 皮質類固醇
  • 醫療器材與設備
    • 外科器械
    • 雷射設備
    • 診斷和影像設備
    • 植入

第8章 視網膜疾病治療市場：依給藥途徑分類

  • 玻璃體內注射
  • 口服
  • 視網膜下

第9章 視網膜疾病治療市場：依疾病適應症分類

  • 黃斑部病變
    • 老齡化黃斑部病變）
    • 濕性老齡化黃斑部病變
  • 糖尿病視網膜病變
    • 不繁殖
    • 增殖
  • 視網膜靜脈阻塞
    • 分支靜脈阻塞
    • 中心靜脈阻塞
  • 葡萄膜炎

第10章 視網膜疾病治療市場：依最終使用者分類

  • 門診手術中心
  • 專科診所
  • 家庭醫療保健
  • 醫院

第11章 視網膜疾病治療市場：依通路分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第12章 視網膜疾病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 視網膜疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 視網膜疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • F. Hoffmann-La Roche Ltd
  • REGENERON PHARMACEUTICALS, INC.
  • Novartis AG
  • AbbVie Inc.
  • Bayer AG
  • Sanofi SA
  • Sandoz Group AG
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Eli Lilly and Company
  • Abbott Laboratories
  • Adverum Biotechnologies
  • Alimera Sciences, Inc. by ANI Pharmaceuticals, Inc.
  • Bausch+Lomb Corporation
  • Biogen Inc.
  • Clearside Biomedical
  • EyeBio by Merck KGaA
  • EyePoint Pharmaceuticals, Inc.
  • GSK plc
  • Kodiak Sciences GmbH
  • MeiraGTx Holdings plc
  • Nanoscope Therapeutics
  • Oculis SA
  • ONL Therapeutics
  • Oxford Biomedica PLC
  • Oxurion NV
  • ReNeuron
  • Samsung Bioepis
Product Code: MRR-CA17E905E6E9

The Retinal Disorder Treatment Market is projected to grow by USD 26.21 billion at a CAGR of 8.07% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.22 billion
Estimated Year [2026] USD 16.40 billion
Forecast Year [2032] USD 26.21 billion
CAGR (%) 8.07%

Retinal disorder treatment is moving from reactive vision preservation to earlier diagnosis, durable disease control, and precision intervention. Demand is driven by aging populations, diabetes prevalence, and broader use of retinal imaging in primary care and ophthalmology settings. The World Health Organization reports that at least 2.2 billion people live with near or distance vision impairment, with at least 1 billion cases preventable or unaddressed, underscoring the need for scalable retinal care.

Key treatment areas include neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, inherited retinal dystrophies, and geographic atrophy. Anti-VEGF therapy remains the standard for several high-burden retinal diseases, while complement inhibitors, gene therapy, sustained-release implants, biosimilars, and AI-enabled screening are reshaping clinical pathways. The International Diabetes Federation estimates that 537 million adults were living with diabetes in 2021, reinforcing the clinical urgency around diabetic retinopathy screening and timely retinal intervention.

Transformative Shifts in the Retinal Treatment Landscape

The retinal disorder treatment landscape is being transformed by longer-acting biologics, new mechanisms of action, and a stronger focus on treatment durability. Regulatory approvals of complement inhibitors for geographic atrophy and established use of gene therapy for confirmed biallelic RPE65 mutation-associated retinal dystrophy demonstrate a shift toward disease-modifying and precision approaches.

Commercial and clinical models are also changing. Ophthalmology practices are balancing high procedure volumes, real-world adherence challenges, drug acquisition costs, and payer requirements. Biosimilar anti-VEGF competition is increasing pricing pressure, while premium innovation is concentrated in products that reduce injection burden, extend dosing intervals, improve anatomical outcomes, or address previously untreatable disease stages.

Cumulative Impact of Artificial Intelligence in Retinal Care

Artificial intelligence is becoming a practical enabler across retinal disorder treatment, especially in diabetic retinopathy screening, image triage, disease progression monitoring, and workflow optimization. The first autonomous AI system for diabetic retinopathy detection received regulatory authorization in 2018, validating AI as a regulated clinical tool rather than a purely experimental technology.

AI can improve access by identifying patients who need referral before irreversible vision loss occurs. It also supports more consistent grading of fundus photographs and OCT images, helps manage large imaging volumes, and may improve clinical-trial enrollment through phenotype identification. Adoption depends on data quality, bias control, interoperability, cybersecurity, reimbursement alignment, and clinician trust, particularly as health systems integrate AI into primary care, endocrinology, optometry, and ophthalmology workflows.

Key Regional Insights Across Retinal Disorder Treatment

Asia-Pacific is a pivotal region for retinal disorder treatment due to large diabetes populations, rapid aging, urban eye-care expansion, and rising use of optical coherence tomography and fundus imaging. China, India, Japan, Australia, and South Korea anchor regional activity, supported by expanding tertiary ophthalmology capacity and greater use of intravitreal therapies. However, affordability, rural access, screening continuity, and specialist distribution remain uneven, making scalable diabetic retinopathy screening and cost-effective anti-VEGF access key priorities.

North America leads in biologic adoption, clinical trials, reimbursement infrastructure, and AI-enabled screening deployment, with the United States anchoring regulatory and clinical innovation and Canada benefiting from structured public coverage frameworks. Europe benefits from universal health systems, strong ophthalmology networks, established clinical guidelines, and structured health technology assessment, although reimbursement timing and injection capacity vary across countries. Latin America is expanding access to anti-VEGF therapy and retinal screening, led by Brazil and Mexico, but cost barriers and specialist concentration continue to affect treatment continuity. The Middle East is upgrading tertiary eye-care capacity through national health transformation programs, particularly across high-income Gulf economies with elevated diabetes prevalence. Africa faces the greatest screening and treatment access gaps, despite rising diabetes burden and preventable vision loss, creating a strong need for mobile screening, workforce training, and affordable treatment pathways.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding retinal screening and treatment capacity as diabetes prevalence, urban healthcare investment, and digital health adoption rise, although affordability and ophthalmologist density differ widely across member states. The GCC is prioritizing specialty hospitals, digital health infrastructure, premium therapeutics, and chronic disease management, supported by national health transformation programs and high diabetes prevalence that increases the need for diabetic retinopathy screening and long-term retinal care.

The European Union is shaped by centralized regulatory evaluation, country-level reimbursement decisions, strong clinical evidence requirements, and health technology assessment processes that influence therapy adoption timelines. BRICS markets represent substantial patient volume, growing clinical infrastructure, and manufacturing potential, particularly in China, India, and Brazil, but access and reimbursement remain heterogeneous across income groups and geographies. G7 countries lead in retinal research, advanced imaging, anti-VEGF utilization, gene-based innovation, and early adoption of new product launches. NATO members overlap significantly with advanced ophthalmic care markets in North America and Europe, where defense-related healthcare systems, public reimbursement structures, and mature specialty networks can support adoption of proven retinal technologies.

Key Country Insights in Retinal Disorder Treatment

The United States leads retinal disorder treatment through high biologic use, strong clinical trial activity, regulatory adoption of AI-enabled diabetic retinopathy screening, and rapid uptake of new retinal therapies when reimbursement conditions are favorable. Canada benefits from public coverage frameworks, organized specialty care, and strong academic ophthalmology networks, while Mexico and Brazil are expanding access through public-private care networks, urban specialty centers, and growing awareness of diabetes-related eye disease.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature ophthalmology systems, established retinal imaging capacity, and guideline-driven treatment pathways, although reimbursement decisions, clinic capacity, and intravitreal injection volumes shape treatment speed and patient persistence. Russia has substantial unmet need across diabetic and age-related retinal disease, with access influenced by regional healthcare variation and diagnostic capacity. China and India represent major long-term demand pools due to large populations, aging demographics, and high diabetes burden, while Japan combines advanced retinal care with one of the world's oldest population profiles. Australia and South Korea show strong imaging adoption, specialist capability, and interest in durable therapies, supported by developed healthcare infrastructure and growing emphasis on early detection.

Actionable Recommendations for Retinal Disorder Treatment Leaders

Industry leaders should prioritize therapies that demonstrate durable efficacy, safety, real-world adherence benefits, and clear health-economic value. Reducing injection burden, improving patient persistence, and addressing earlier disease stages can create measurable differentiation in crowded anti-VEGF segments, especially as biosimilars intensify pricing pressure and payers scrutinize treatment frequency.

Organizations should invest in AI-compatible diagnostics, decentralized screening partnerships, referral pathway optimization, and evidence generation across diverse populations. Market access teams need country-specific pricing, reimbursement, tender, and evidence strategies, while manufacturers should prepare for biosimilar pressure through lifecycle management, patient-support services, supply reliability, and outcomes-based evidence. Partnerships with primary care, endocrinology, optometry, and teleophthalmology networks can improve screening-to-treatment conversion and reduce avoidable vision loss.

Research Methodology for Retinal Disorder Treatment Analysis

This executive summary is developed using secondary research from validated public and industry sources, including global health agencies, regulatory databases, peer-reviewed ophthalmology literature, clinical-trial registries, disease epidemiology publications, and public health guidance. Data points are cross-checked for consistency across recognized sources such as WHO, IDF, regulatory agencies, CDC, NIH/NEI, and major ophthalmology associations.

The methodology integrates disease burden analysis, treatment pathway assessment, regulatory review, regional access evaluation, technology trend mapping, and clinical practice considerations. Insights are synthesized to reflect current evidence, commercially relevant shifts, and practical implications for stakeholders in retinal disorder treatment, while avoiding market sizing, market share, or forecasting claims.

Conclusion: Future Direction of Retinal Disorder Treatment

Retinal disorder treatment is entering a more diversified era defined by biologic durability, AI-enabled detection, precision medicine, and expanding access models. Anti-VEGF therapy remains foundational, but complement inhibition, gene therapy, biosimilars, sustained-delivery approaches, and digital screening are widening the therapeutic and diagnostic field.

Organizations that align innovation with affordability, workflow efficiency, reimbursement evidence, and regional access needs will be best positioned to improve clinical outcomes. The strongest opportunities lie in preventing avoidable vision loss, extending treatment intervals, enabling earlier diagnosis, and building integrated diagnostic-to-treatment ecosystems that connect screening, referral, treatment, and long-term monitoring.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Retinal Disorder Treatment Market, by Treatment Modality

  • 7.1. Pharmacotherapy (Drugs)
    • 7.1.1. Anti-VEGF
    • 7.1.2. Corticosteroids
  • 7.2. Devices & Instruments
    • 7.2.1. Surgical Devices
    • 7.2.2. Laser Devices
    • 7.2.3. Diagnostic & Imaging Devices
    • 7.2.4. Implants

8. Retinal Disorder Treatment Market, by Route Of Administration

  • 8.1. Intravitreal Injection
  • 8.2. Oral
  • 8.3. Subretinal

9. Retinal Disorder Treatment Market, by Disease Indication

  • 9.1. Macular Degeneration
    • 9.1.1. Dry Age-Related Macular Degeneration
    • 9.1.2. Wet Age-Related Macular Degeneration
  • 9.2. Diabetic Retinopathy
    • 9.2.1. Nonproliferative
    • 9.2.2. Proliferative
  • 9.3. Retinal Vein Occlusion
    • 9.3.1. Branch Vein Occlusion
    • 9.3.2. Central Vein Occlusion
  • 9.4. Uveitic Disease

10. Retinal Disorder Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Specialized Clinics
  • 10.3. Home Healthcare
  • 10.4. Hospitals

11. Retinal Disorder Treatment Market, by Distribution Channel

  • 11.1. Offline
    • 11.1.1. Hospital Pharmacy
    • 11.1.2. Retail Pharmacy
  • 11.2. Online

12. Retinal Disorder Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Retinal Disorder Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Retinal Disorder Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. F. Hoffmann-La Roche Ltd
  • 16.2. REGENERON PHARMACEUTICALS, INC.
  • 16.3. Novartis AG
  • 16.4. AbbVie Inc.
  • 16.5. Bayer AG
  • 16.6. Sanofi SA
  • 16.7. Sandoz Group AG
  • 16.8. Amgen Inc.
  • 16.9. Apellis Pharmaceuticals, Inc.
  • 16.10. Teva Pharmaceutical Industries Ltd.
  • 16.11. Cipla Limited
  • 16.12. Eli Lilly and Company
  • 16.13. Abbott Laboratories
  • 16.14. Adverum Biotechnologies
  • 16.15. Alimera Sciences, Inc. by ANI Pharmaceuticals, Inc.
  • 16.16. Bausch + Lomb Corporation
  • 16.17. Biogen Inc.
  • 16.18. Clearside Biomedical
  • 16.19. EyeBio by Merck KGaA
  • 16.20. EyePoint Pharmaceuticals, Inc.
  • 16.21. GSK plc
  • 16.22. Kodiak Sciences GmbH
  • 16.23. MeiraGTx Holdings plc
  • 16.24. Nanoscope Therapeutics
  • 16.25. Oculis S.A.
  • 16.26. ONL Therapeutics
  • 16.27. Oxford Biomedica PLC
  • 16.28. Oxurion NV
  • 16.29. ReNeuron
  • 16.30. Samsung Bioepis

LIST OF FIGURES

  • FIGURE 1. GLOBAL RETINAL DISORDER TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RETINAL DISORDER TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACOTHERAPY (DRUGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOTHERAPY (DRUGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOTHERAPY (DRUGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-VEGF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-VEGF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-VEGF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DEVICES & INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DEVICES & INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DEVICES & INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SURGICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SURGICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LASER DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LASER DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LASER DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC & IMAGING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC & IMAGING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC & IMAGING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUBRETINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUBRETINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUBRETINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NONPROLIFERATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NONPROLIFERATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NONPROLIFERATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROLIFERATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROLIFERATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROLIFERATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RETINAL VEIN OCCLUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RETINAL VEIN OCCLUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RETINAL VEIN OCCLUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRANCH VEIN OCCLUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRANCH VEIN OCCLUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRANCH VEIN OCCLUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL VEIN OCCLUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CENTRAL VEIN OCCLUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CENTRAL VEIN OCCLUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UVEITIC DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UVEITIC DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UVEITIC DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 183. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 207. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 219. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 231. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 235. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 256. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 327. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 328. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 329. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 331. RUSSIA RETINAL DIS